Q3 FY2026 · ended Sep 30, 2026 · Revenue $3.44B, +11.8% YoY · Filed Nov 3, 2026
Vertex Pharmaceuticals Inc / Ma (VRTX) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $3.4 billion and net income of $653.6 million. Free cash flow was $545.8 million. As of Sep 30, 2026 it held $9.8 billion in cash and investments and $6.5 billion in total debt.
Revenue
$3.44B
+11.8% vs year-ago quarter
Net income
$653.60M
-39.6% vs year-ago quarter
Operating cash flow
$643.10M
-48.2% vs year-ago quarter
Free cash flow
$545.80M
-52.1% vs year-ago quarter
EPS
$2.56
-39.0% vs year-ago quarter
Dividend per share
None
Shares outstanding
253.54M
-0.1% vs year-ago quarter
Net cash
$3.34B
Q3 FY2026
Operating margin
33.2%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- VRTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- MA
- Headquarters
- Boston, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 875320
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $3.4B | $3.3B | $3.0B | $3.2B | $3.1B |
| Operating income | $712.9M | $1.2B | $1.1B | $1.2B | $1.2B |
| Net income | $653.6M | $1.1B | $1.0B | $1.2B | $1.1B |
| Diluted EPS | $2.56 | $4.31 | $4.02 | $4.65 | $4.20 |
| Operating cash flow | $643.1M | $1.1B | $1.4B | $498.0M | $1.2B |
| Free cash flow | $545.8M | $1.0B | $1.3B | $348.6M | $1.1B |
| Total assets | $32.7B | $27.4B | $26.5B | $25.6B | $24.9B |
| Total liabilities | $11.8B | $7.2B | $7.1B | $7.0B | $7.5B |
| Stockholders' equity | $20.9B | $20.2B | $19.4B | $18.7B | $17.3B |
| Cash and investments | $9.8B | $13.6B | $13.0B | $12.3B | $12.0B |
| Total debt | $6.5B | $2.0B | $2.0B | $2.0B | $1.8B |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 3, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 2, 2026 | Nov 2, 2026 |
| 8-K |
Current report
Officer or director change
|
Oct 20, 2026 | Oct 20, 2026 |
| 8-K |
Current report
Officer or director change
|
Sep 1, 2026 | Aug 27, 2026 |
| 10-Q | Quarterly report | Aug 4, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 3, 2026 | Aug 3, 2026 |
All 1002 Vertex Pharmaceuticals Inc / Ma SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.